.
the software identified and measured a marker of svd and then gave a score indicating how severe the disease was ranging from mild to severe.
.
.
eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
https://grassfed.us/Rehfield-mother-of-Northington-from-Helsinki
.
"the importance of our new method is that it allows for precise and automated measurement of the disease," bentley added in the study published in the journal radiology.
.![stop enabling extremism through ignorance]()
.